Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Why Is Kairos Pharma Stock Surging On Tuesday? | 2 | Benzinga.com | ||
Di | Kairos Pharma Stock Soars After Positive Interim Results From Phase 2 Trial Of ENV-105 | - | RTTNews | ||
Di | Kairos Pharma stock soars after positive safety data for cancer drug | 2 | Investing.com | ||
Di | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
12.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
03.06. | Kairos Pharma präsentiert vielversprechende Daten zu Krebsmedikament | 1 | Investing.com Deutsch | ||
03.06. | Kairos Pharma presents promising cancer drug data | 1 | Investing.com | ||
03.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
14.05. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | D.Boral Capital: Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference | 111 | Newsfile | Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place... ► Artikel lesen | |
24.04. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
24.04. | Kairos Pharma treibt Krebsmedikamententests voran und erweitert Standorte | 2 | Investing.com Deutsch | ||
24.04. | Kairos Pharma advances cancer drug trials, expands sites | 2 | Investing.com | ||
21.04. | H.C. Wainwright maintains Buy on Kairos Pharma shares, $12 target | 1 | Investing.com | ||
15.04. | Kairos Pharma, LTD. - 10-K, Annual Report | 1 | SEC Filings | ||
03.04. | H.C. Wainwright sets $12 target for Kairos Pharma stock | 1 | Investing.com | ||
31.03. | Kairos Pharma treibt Phase-2-Studie für Prostatakrebs voran | 1 | Investing.com Deutsch | ||
31.03. | Kairos Pharma advances phase 2 trial for prostate cancer | 3 | Investing.com | ||
28.03. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105 | 332 | Newsfile | Toronto, Ontario--(Newsfile Corp. - March 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded... ► Artikel lesen | |
20.03. | Kairos Pharma meldet Durchbruch bei Lungenkrebs-Behandlung | 3 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
QIAGEN | 41,050 | -0,86 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,540 | +11,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
BIONTECH | 93,65 | -1,06 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
CRISPR THERAPEUTICS | 57,00 | +1,79 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
ITEOS THERAPEUTICS | 10,300 | +0,29 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
SAB BIOTHERAPEUTICS | 2,950 | +4,98 % | SAB Biotherapeutics sichert sich 175 Mio. US-Dollar über Privatplatzierung - Aktie legt um 33 % zu | ||
AVIDITY BIOSCIENCES | 34,920 | +3,50 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,230 | +2,41 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
180 LIFE SCIENCES | 3,220 | +71,28 % | 180 Life Sciences beschleunigt Zuteilung von Aktienvergütungen für Führungskräfte | ||
SUMMIT THERAPEUTICS | 26,630 | +1,64 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
REDHILL BIOPHARMA | 2,820 | +46,11 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
ABSCI | 3,570 | +14,24 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
BRUKER | 30,700 | -12,03 % | Bruker-Aktie bricht nach Umsatzwarnung für Q2 ein | ||
VERVE THERAPEUTICS | 10,990 | +0,69 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly |